- Home
- FIGS vs AMPH Comparison
FIGS vs AMPH Comparison
Compare FIGS & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- AMPH
- Stock Information
- Founded
- FIGS 2013
- AMPH 1996
- Country
- FIGS United States
- AMPH United States
- Employees
- FIGS N/A
- AMPH N/A
- Industry
- FIGS Apparel
- AMPH Biotechnology: Pharmaceutical Preparations
- Sector
- FIGS Consumer Discretionary
- AMPH Health Care
- Exchange
- FIGS Nasdaq
- AMPH Nasdaq
- Market Cap
- FIGS 1.1B
- AMPH 1.2B
- IPO Year
- FIGS 2021
- AMPH 2014
- Fundamental
- Price
- FIGS $6.98
- AMPH $25.99
- Analyst Decision
- FIGS Sell
- AMPH Buy
- Analyst Count
- FIGS 4
- AMPH 6
- Target Price
- FIGS $5.38
- AMPH $35.50
- AVG Volume (30 Days)
- FIGS 2.0M
- AMPH 454.6K
- Earning Date
- FIGS 11-06-2025
- AMPH 11-05-2025
- Dividend Yield
- FIGS N/A
- AMPH N/A
- EPS Growth
- FIGS N/A
- AMPH N/A
- EPS
- FIGS 0.04
- AMPH 2.68
- Revenue
- FIGS $569,581,000.00
- AMPH $722,679,000.00
- Revenue This Year
- FIGS $4.63
- AMPH $1.37
- Revenue Next Year
- FIGS $3.69
- AMPH $6.93
- P/E Ratio
- FIGS $160.76
- AMPH $9.68
- Revenue Growth
- FIGS 3.41
- AMPH 1.37
- 52 Week Low
- FIGS $3.57
- AMPH $20.39
- 52 Week High
- FIGS $7.54
- AMPH $53.96
- Technical
- Relative Strength Index (RSI)
- FIGS 51.93
- AMPH 38.56
- Support Level
- FIGS $6.50
- AMPH $25.96
- Resistance Level
- FIGS $7.38
- AMPH $27.31
- Average True Range (ATR)
- FIGS 0.25
- AMPH 0.73
- MACD
- FIGS 0.00
- AMPH -0.14
- Stochastic Oscillator
- FIGS 49.49
- AMPH 6.14
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.